Cargando…

Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines

Chikungunya virus (CHIKV) is an alphavirus associated with a broad tissue tropism for which no antivirals or vaccines are approved. This study evaluated the antiviral potential of favipiravir (FAV), interferon-alpha (IFN), and ribavirin (RBV) against CHIKV as mono- and combination-therapy in cell li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franco, Evelyn J., Tao, Xun, Hanrahan, Kaley C., Zhou, Jieqiang, Bulitta, Jürgen B., Brown, Ashley N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912990/ https://www.ncbi.nlm.nih.gov/pubmed/33540830 http://dx.doi.org/10.3390/microorganisms9020307

Ejemplares similares

Favipiravir Inhibits Zika Virus (ZIKV) Replication in HeLa Cells by Altering Viral Infectivity
por: Franco, Evelyn J., et al.
Publicado: (2023)

Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
por: Franco, Evelyn J., et al.
Publicado: (2023)

Why Molnupiravir Fails in Hospitalized Patients
por: Brown, Ashley N., et al.
Publicado: (2022)

The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines
por: Franco, Evelyn J, et al.
Publicado: (2018)

Favipiravir Does Not Inhibit Chikungunya Virus Replication in Mosquito Cells and Aedes aegypti Mosquitoes
por: Jacobs, Sofie, et al.
Publicado: (2021)

Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus
por: Franco, Evelyn J., et al.
Publicado: (2021)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression
por: Franco, Evelyn J., et al.
Publicado: (2023)

Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens
por: Cheah, Soon-Ee, et al.
Publicado: (2016)

Favipiravir elicits antiviral mutagenesis during virus replication in vivo
por: Arias, Armando, et al.
Publicado: (2014)

Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma
por: Sainz, Bruno, et al.
Publicado: (2005)

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen
por: Bulitta, Jürgen B, et al.
Publicado: (2021)

Imidazonaphthyridine effects on Chikungunya virus replication: Antiviral activity by dependent and independent of interferon type 1 pathways
por: Ruiz, Uriel Enrique Aquino, et al.
Publicado: (2022)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
por: Huang, Yin-Qiu, et al.
Publicado: (2020)

Silvestrol Inhibits Chikungunya Virus Replication
por: Henss, Lisa, et al.
Publicado: (2018)

Architecture of the chikungunya virus replication organelle
por: Laurent, Timothée, et al.
Publicado: (2022)

Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir
por: Comer, Jason E., et al.
Publicado: (2019)

Molecular architecture of the Chikungunya virus replication complex
por: Tan, Yaw Bia, et al.
Publicado: (2022)

An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
por: Sarojvisut, Phahol, et al.
Publicado: (2023)

Favipiravir-based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn
por: Moolasart, Visal, et al.
Publicado: (2020)

Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens
por: Mikhail, Ibraam E., et al.
Publicado: (2021)

Interferon Alpha Induces Cellular Autophagy and Modulates Hepatitis B Virus Replication
por: Li, Jia, et al.
Publicado: (2022)

Interferon-alpha responsible EPN3 regulates hepatitis B virus replication
por: Li, Xueqian, et al.
Publicado: (2022)

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)
por: Pires de Mello, Camilly P., et al.
Publicado: (2018)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
por: Brown, Ashley N., et al.
Publicado: (2021)

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models
por: Kim, Ji-Ae, et al.
Publicado: (2018)

Deubiquitinating Enzyme Inhibitors Block Chikungunya Virus Replication
por: López, Lady S., et al.
Publicado: (2023)

EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA
por: Delen, Leman Acun, et al.
Publicado: (2022)

Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes
por: Workenhe, Samuel T, et al.
Publicado: (2008)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

The mechanism of resistance to favipiravir in influenza
por: Goldhill, Daniel H., et al.
Publicado: (2018)

Favipiravir in Therapy of Viral Infections
por: Łagocka, Ryta, et al.
Publicado: (2021)

Favipiravir: Hyperuricaemia: case report
Publicado: (2021)

Calpain-2 protein influences chikungunya virus replication and regulates vimentin rearrangement caused by chikungunya virus infection
por: Li, Jia, et al.
Publicado: (2023)

Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice
por: Kiso, Maki, et al.
Publicado: (2020)

Chikungunya triggers an autophagic process which promotes viral replication
por: Krejbich-Trotot, Pascale, et al.
Publicado: (2011)

Chikungunya Virus Replication in Salivary Glands of the Mosquito Aedes albopictus
por: Vega-Rúa, Anubis, et al.
Publicado: (2015)

Trigocherrierin A, a Potent Inhibitor of Chikungunya Virus Replication
por: Bourjot, Mélanie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_630h880f4v6nuks5ipojgt6c1g